A Phase 3 interventional study of Combination drug and Chemoradiotherapy in Recurrent Rectal Cancer, sponsored by Catharina Ziekenhuis Eindhoven. Recruiting at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-06.
Sponsored by Catharina Ziekenhuis Eindhoven · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Rectal Neoplasms with a site in Netherlands — 21 open to participants now, 32 under way, 8 of them phase 3. Rectal Neoplasms · Netherlands.
Among the 74 studies in Rectal Neoplasms with a site in Netherlands, this one is the 14th largest by planned enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2020, is one of 19 in phase 3, reaches primary completion later than 3 of the 31 other live ones, and was the 44th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →21 of the 74 studies in Rectal Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
Heike M.U. Peulen · Sites in Netherlands
Ages 18+
Maastricht Radiation Oncology · Sites in Netherlands
Ages 18+
Claudia Schuurhuizen · Sites in Netherlands
Ages 18+
GlaxoSmithKline · Sites in Netherlands, United States, Canada and 6 more countries
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 21 · Phase 3 21
First in 1993; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 364 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 108 across the 59 interventional studies, 133 across the 14 observational. Of the 30 that completed or were terminated, 3 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 74 have an industry lead sponsor. The 10 most frequent:
Catharina Ziekenhuis Eindhoven is the lead sponsor of 85 studies on the registry; 16 are open to participants now.
Catharina Ziekenhuis Eindhoven has 2 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT04927897Maastricht Radiation OncologyDETECT: Target Volume for Rectal Endoluminal Radiation Boosting | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 74 studies in Rectal Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
Drug: Combination drug · Radiation: Chemoradiotherapy · Procedure: Surgery locally recurrent rectal cancer
Neoadjuvant chemoradiotherapy followed by surgery
Radiation: Chemoradiotherapy · Procedure: Surgery locally recurrent rectal cancer
Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles. If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI.
Also known as: CAPOX, FOLFOX, FOLFIRI
Concomitant chemotherapy agent: capecitabine Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy.
Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon. Intraoperative radiotherapy is optional.
Proportion of patients with a clear resection margin
A resection margin is considered clear (R0), if there are no tumour cells in any of the resection surfaces as determined by microscopy (resection margin \> 0mm)
Time frame: Scored within 1 one month of surgery
Local recurrence free survival
Time frame: Assessed up to 5 years
Progression free survival
Time frame: Assessed up to 5 years
Metastasis free survival
Time frame: Assessed up to 5 years
Disease free survival
Time frame: Assessed up to 5 years
Overall survival
Time frame: Assessed up to 5 years
Pathologic response
Scored according to Mandard
Time frame: Scored within 1 month of surgery
Toxicity induction chemotherapy
Adverse events grade 3 or higher according to the NCI-CTCAE v5.0
Time frame: Scored until one month after the last administration of the chemotherapy
Compliance induction chemotherapy
Time frame: Scored within 1 month after start chemoradiotherapy
Toxicity chemoradiotherapy
Adverse events grade 3 or higher according to the NCI-CTCAE v5.0
Time frame: Scored until 3 months after the last administration of the radiotherapy
Compliance chemoradiotherapy
Time frame: Evaluation at time of surgery
Number of patients undergoing surgery
Time frame: Surgery is scheduled 10-14 weeks after finishing chemoradiotherapy
Surgical characteristics
including data on intra-operative radiotherapy
Time frame: Evaluation directly postoperative
Major surgical morbidity
Clavien-Dindo grade 3 or higher
Time frame: 30 and 90-days postoperative
Radiological response
mrTRG
Time frame: Restaging is performed after 3 cycles of CAPOX (1 cycle is 3 weeks) or 4 cycles of CAPOX/FOLFOX (1 cycle is 2 weeks). Second restaging is performed 4-6 weeks after finishing chemoradiotherapy
Cancer specific quality of life
QLQ-C30
Time frame: at baseline, 3 months and 12 months postoperative
Cost-effectiveness
EQ-5D-5L
Time frame: at baseline, 3 months and 12 months postoperative
Colorectal cancer specific quality of life
QLQ-CR29
Time frame: at baseline, 3 months and 12 months postoperative
Plan to share: Yes — Participant-level datasets and statistical codes will become available upon reasonable request after the results of the study have been published.
Supporting information: Study protocol, Informed consent form
Time frame: The full protocol and Dutch informed consent forms are publicly accessible after approval of the medical ethics committee.
No publications or documents are linked to this record.
Started Nov 2020 (actual). Primary completion is estimated for Mar 2024, 39 months after the start.
Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 39 months is below that.
Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Catharina Ziekenhuis Eindhoven